Something to think about... Paxlovid was expect
Post# of 1418
(Total Views: 217)
Posted On: 05/06/2022 11:58:06 AM
Something to think about...
Paxlovid was expected to add $25B to Pfizer's bottom line
That's not what Paxlovid valuation is, but just what Pfizer was expecting in revenue in one year.
Didn't even include long covid as Pfizer has no trials and 3 case studies. The same amount as little Todos.
So what was the valuation of Paxlovid? $100B, $200B, $300B. Remember the $25B was likely all they could produce and only certain markets.
Think about what the valuation of Tollovid would be worth, that doesn't have the side effects, conditions, risk and the...you have to take it within 5 days of getting infected, oh and need to see a doctor and get a prescription baggage.
Now factor in the potential of Tollovid working in some patients. Still early and maybe it doesn't pan out for LC, but a lot of shots on goals with preventive, mild, severe, hospitalized patients and now long covid.
Paxlovid was expected to add $25B to Pfizer's bottom line
That's not what Paxlovid valuation is, but just what Pfizer was expecting in revenue in one year.
Didn't even include long covid as Pfizer has no trials and 3 case studies. The same amount as little Todos.
So what was the valuation of Paxlovid? $100B, $200B, $300B. Remember the $25B was likely all they could produce and only certain markets.
Think about what the valuation of Tollovid would be worth, that doesn't have the side effects, conditions, risk and the...you have to take it within 5 days of getting infected, oh and need to see a doctor and get a prescription baggage.
Now factor in the potential of Tollovid working in some patients. Still early and maybe it doesn't pan out for LC, but a lot of shots on goals with preventive, mild, severe, hospitalized patients and now long covid.
(1)
(0)Todos Med Ltd. (TOMDF) Stock Research Links
Scroll down for more posts ▼